CANTOS Trial Validates the Inflammatory Pathogenesis of Atherosclerosis Setting the Stage for a New Chapter in Therapeutic Targeting

Weber, Christian und Hundelshausen, Philipp von (2017): CANTOS Trial Validates the Inflammatory Pathogenesis of Atherosclerosis Setting the Stage for a New Chapter in Therapeutic Targeting. In: Circulation Research, Bd. 121, Nr. 10: S. 1119-1121

Abstract

The CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) provides intriguing support for the inflammatory hypothesis of atherosclerosis and cancer in man, demonstrating diverse clinical benefits of inhibiting IL (interleukin)-1 beta for cardiovascular events and lung cancer. Limited effects on cardiovascular mortality and safety concerns raised by a higher incidence of fatal infection warrant further studies to identify patient subgroups which profit most from anti-inflammatory therapy and a careful pursuit of alternative targets.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0009-7330
• Sprache: Englisch